Endometriosis Treatment Report

www.EndometriosisTreatmentReport.com

Phase 3

DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

https://clinicaltrials.gov/ct2/show/NCT01942122?type=Intr

https://clinicaltrials.gov/ct2/show/NCT01942122?type=Intr&cond=Endometriosis&lupd_s=07%2F08%2F2020&lupd_d=14

Conditions :   Endometrioma;   Visual Analogue Pain Scale: Moderate or Severe Pain

Interventions :   Drug: DLBS1442 100;   Drug: Mefenamic acid;   Drug: DLBS1442 200

Sponsor :   Dexa Medica Group

Recruiting

DLBS1442 for The Treatment of Pain in Patients Suspected Endometriosis

NCT01942122

Fri, 13 Sep 2013 12:00:00 EDT

Last Update Posted: 07/22/20 08:19AM

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

https://clinicaltrials.gov/ct2/show/NCT03986944?type=Intr

https://clinicaltrials.gov/ct2/show/NCT03986944?type=Intr&cond=Endometriosis&lupd_s=04%2F17%2F2020&lupd_d=14

Condition :   Endometriosis

Interventions :   Drug: 75 mg linzagolix tablet;   Drug: 200 mg linzagolix tablet;   Drug: Add-back capsule (E2 1 mg / NETA 0.5 mg);   Drug: Placebo tablet to match 75 mg linzagolix tablet;   Drug: Placebo tablet to match 200 mg linzagolix tablet;   Drug: Placebo capsule to match Add-back capsule

Sponsor :   ObsEva SA

Recruiting

A Phase 3 Study to Confirm the Efficacy and Safety of Linzagolix to Treat Endometriosis-associated Pain

NCT03986944

Fri, 14 Jun 2019 12:00:00 EDT

Last Update Posted: 05/01/20 08:08AM

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

https://clinicaltrials.gov/ct2/show/NCT03213457?type=Intr&cond=Endometriosis&lupd_s=02%2F21%2F2019&lupd_d=14

Condition :   Endometriosis

Interventions :   Drug: Estradiol/Norethindrone Acetate;   Other: Placebo for Elagolix;   Drug: Elagolix;   Other: Placebo for E2/NETA

Sponsor :   AbbVie

Recruiting

A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated Pain

NCT03213457

Tue, 11 Jul 2017 12:00:00 EDT

Last Update Posted: 03/07/19 12:39PM

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis – A Prospective Double-blind Placebo-controlled Trial

https://clinicaltrials.gov/ct2/show/NCT04173169?type=Intr&cond=Endometriosis&lupd_s=11%2F07%2F2019&lupd_d=14

Conditions :   Infertility;   Endometriosis

Interventions :   Drug: Elagolix 200 MG;   Drug: Placebo

Sponsors :   Yale University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   University of Colorado, Denver;   Northwestern University;   University of North Carolina

Not yet recruiting

Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis – A Prospective Double-blind Placebo-controlled Trial

NCT04173169

Thu, 21 Nov 2019 12:00:00 EST

Last Update Posted: 11/21/19 07:46AM

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

https://clinicaltrials.gov/ct2/show/NCT03931915?type=Intr&cond=Endometriosis&lupd_s=04%2F16%2F2019&lupd_d=14

Condition :   Endometriosis

Interventions :   Drug: TAK-385;   Drug: Leuprorelin acetate

Sponsor :   ASKA Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Study to Evaluate Efficacy and Safety of TAK-385 40 mg Compared With Leuprorelin in Patients With Endometriosis

NCT03931915

Tue, 30 Apr 2019 12:00:00 EDT

Last Update Posted: 04/30/19 11:33AM

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

https://clinicaltrials.gov/ct2/show/NCT03204318?type=Intr&cond=Endometriosis&lupd_s=03%2F22%2F2019&lupd_d=14

Condition :   Endometriosis Related Pain

Interventions :   Drug: Relugolix;   Drug: Estradiol/norethindrone acetate;   Drug: Placebo for E2/NETA;   Drug: Placebo for relugolix

Sponsor :   Myovant Sciences GmbH

Recruiting

SPIRIT 1: Efficacy and Safety Study of Relugolix in Women With Endometriosis-Associated Pain

NCT03204318

Sun, 02 Jul 2017 12:00:00 EDT

Last Update Posted: 04/05/19 08:45AM

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Subjects With Endometriosis

https://clinicaltrials.gov/ct2/show/NCT03232281?type=Intr&cond=Endometriosis&lupd_s=03%2F14%2F2019&lupd_d=14

Condition :   Endometriosis

Interventions :   Drug: Triptorelin Pamoate PR 3-month;   Drug: Triptorelin Acetate PR 1-month

Sponsor :   Ipsen

Active, not recruiting

Study to Compare the Oestradiol Suppression, Clinical Efficacy and Safety of Two Formulations of Triptorelin (Triptorelin Pamoate PR 3-month and Triptorelin Acetate PR 1-month) in Chinese Subjects With Endometriosis

NCT03232281

Thu, 27 Jul 2017 12:00:00 EDT

Last Update Posted: 03/28/19 09:30AM

Back to top